Get to know our clinical trials
Clinical trial to evaluate the efficacy of MaaT013 as salvage therapy in patients with acute GVHD with gastrointestinal involvement, resistant to ruxolitinib.
THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE OVERALL RESPONSE RATE (ORR: COMPLETE RESPONSE PARTIAL RESPONSE VERY GOOD PARTIAL RESPONSE) OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) ON DAY 28.
- EVALUATION OF THE EFFICACY OF MAAT013 AS SALVAGE THERAPY IN PATIENTS WITH ACUTE GVHD WITH GASTROINTESTINAL INVOLVEMENT, REFRACTORY TO RUXOLITINIB; PHASE III, MULTICENTER, OPEN-LABEL TRIAL.
- Code EudraCT: 2021-001841-11
- Protocol number: MPOH06
- Promoter: Maat Pharma
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.